review research scienc behind trhc
spend time manag team understand
scienc behind mtm person medicin offer convinc
uniqu approach make person medicin mainstream unlik
tradit drug interact system reli drug label evidence-
base interact trhc method reli risk profil medic plan
overlay enzyme-level metabol info across patient drug ingredi
combin identifi potenti advers effect efficaci issu method
much comprehens identifi issu beyond list drug label
addit patient genet approach result much precis
person medicin increas pt reiter outperform
scienc vastli simplifi form map medic metabol
patient genet avail build matrix patient drug
enzyme-level pathway identifi drug combin conflict influenc
efficaci dramat increas identif problem combin
compar tradit drug label-depend interact
recommend improv outcom quality-of-lif use map
patient score variou risk factor side effect burden compet
med etc plan deriv reduc patient risk layer
adjust time variou drug intak find altern medic
combin and/or work physician priorit dose
opportun take person medicin mainstream compani
concentr pace market recent
commerci market believ vast opportun take person
medic offer mainstream convinc improv patient
outcom methodolog believ offer direct consum
and/or retail pharmaci inevit
pipelin encourag anticip multipl lever drive deal flow
near term recent cmss chang nudg plan toward
mtm servic new part requir opioid misus posit trhc
sinfoniarx pipelin convers like provid deal drive servic mix
introduc estim rais introduc
estim top-lin growth also increas
price target base revenu prior target
saa compani believ opportun person
medicin scarciti valu drive valuat higher
proprietari
reduc
technolog servic
medic safeti patient outcom
lower healthcar cost client
analyst certif import disclosur see disclosur
tabula rasa proprietari medic risk therapi solut
enabl signific shift care elderli
pace focus elimin advers drug event
deal complex multiple-med regimen home
demograph tailwind increas use multipl medic
cost focu drive penetr non-
profit for-profit pace program trhc solut
mtm mrm solut signific relev
commerci health plan expect see wave
adopt commerci plan sinfoniarx acquisit add new
solut acceler growth
continu growth sustain oper margin improv
contract new pace organ
new commerci contract emtm medwis solut
sinfoniarx earnout pipelin convert contract
sinfoniarx earnout lift growth significantli
mix new live tilt commerci live penetr
sinfoniarx earnout convert impact expect
new market entrant pose headlin risk potenti take
regulatori chang disrupt pace adopt
increas price target base revenu prior target saa compani
believ opportun person medicin uniqu valu asset drive valuat higher
near term integr sinfoniarx acquisit convert earnout pipelin pose biggest risk stori regulatori
turmoil disrupt pace could impact growth increas attent mtm could attract competit
evid base vs person medicin broader term drug discoveri
approv driven evidence-bas drug trial evidence-bas methodolog show
evid particular drug result desir outcom improv health doesnt
necessarili explor possibl scenario conflict effect drug particular individu
uniqu model help translat evid base medicin person medicinebi
combin genet patient pharmacokinet drug combin
result much improv outcom patient
decreas cost genet test add tailwind precis person medicin
dramat increas add patient genet matrix studi medic
metabol pathway broader group patient individu patient gene influenc
efficaci medic simpl metabol rate enzym dictat gene indic
effect medic go leverag individu medic dosag
requir recent year cost genet test come dramat
rang make realiti access easier econom genet test grow believ
interest person medicin also increas
sizabl first mover advantag competitor data map new drug
public avail trhc secret sauc interpret data reduc advers drug event
simpli boost adher trigger clinician alarm fatigu over-flag potenti drug interact
mtm technolog consid multi-drug interact patent sever pend
also eight year outcom data lower hospit fall track record
partnership opportun horizon believ greater clinic integr major
emr pharmaci chain like distant futur major pharmaci chain particular
look boost custom sticki threat new entrant could
also work drugmak prevent futur on-market drug issu initi launch
accept recommend vari market pace doc accept trhc
recommend accept lower non-pac market given eprescrib higher overlap
among pace patient howev recently-train physician open
emtm pilot year serv six region northern plain bcb part live
year two focu shift empow patient empow commun pharmaci
medwis advisor demo pharmaci school prescrib decis support tool spider-
web graph five risk factor qt interv sdv burden ach burden competit inhibit side
effect second side effect chart may includ shock potenti drug abus competit inhibit
consid affin coeffici percentag drug like metabol among differ
biolog pathway word drug first get park spot
henc perform intend biolog function
medwis advisor simpl recommend quality-of-lif improv addit
risk score correl health outcom cost medwis advisor produc
fridg report may instruct patient space medic throughout day
medic breakfast medic dinner simpl chang patient
drug allevi side effect drowsi risk fall critic medic
ineffect medwis advisor also provid report patient share side effect
doctor importantli report directli physician limit suggest medic chang
potenti result improv patient risk score
genet test frontier roughli trhc patient done genet test today
cheek swab good lifetim test enabl custom view
medic interact base specif gene pharmacogenom within pace
patient undergon genet test find variat slow metabol certain
pathway deviat result drug interact
eirenerx pace solut eirenerx similar medwis advisor pace program pace
also includ fill drug often adher packag pill group day time
day current serv pace live
product roadmap futur current look drug metabol futur
may check biolog transport mechan receptor site compat hope move precis
medicin predict medicin drug like get outcom tabula rasa also
hope use ai autom rule reduc need human pharmacist involv
scale ad key leader help scale employ pr firm build public
awar offer anticip solut may one day fda-regul design
accordingli
growth target comfort organ top-lin growth next sever year
growth pace core market well recent sinfonarx win open accret acquisit
especi manag medicaid mtm
eu opportun color larg intern opportun european pharmaci
group softwar use countri client well known
also develop manag hospit
introduc estim introduc estim top-lin growth flat
ebitda margin believ upsid estim compani
manag continu target revenu growth estim
revenu mix shift toward servic margin improv toward
research develop
sale market
gener administr
depreci amort
chang fair valu warrant liabil
loss extinguish debt
total expens
incom tax
dilut prefer stock warrant
compani report oppenheim estim
